Good pharmacovigilance practices

  • Email
  • Help

Good pharmacovigilance practices (GVP) are a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU). GVP apply to marketing-authorisation holders, the European Medicines Agency and medicines regulatory authorities in EU Member States. They cover medicines authorised centrally via the Agency as well as medicines authorised at national level.

Guideline on GVP

The guideline on GVP is divided into chapters that fall into two categories:

  • modules covering major pharmacovigilance processes;
  • product- or population-specific considerations.

Each chapter is developed by a team consisting of experts from the European Medicines Agency and from EU Member States.

The guideline on GVP is a key deliverable of the 2010 pharmacovigilance legislation

Modules covering major pharmacovigilance processes

GVP modules I to XVI cover major pharmacovigilance processes and the development of this set of guidance is concluded. The module numbers XI, XII, XIII and XIV stay void, as their planned topics have been addressed by other guidance documents on the Agency’s website (see  'Related links' box below Final GVP modules table).

Product- or population-specific considerations

The chapters on product- or population-specific considerations have been developed for vaccines and biological medicinal products. Two more considerations chapters are planned as follows:

Chapter numberPreliminary chapter titleDate of release for public consultation
P IIIPregnancy and breast-feedingQ1 2018
P VGeriatric populationQ1 2018

Archives of documents

Table of contents


Introduction

Back to top

Document(s) Language Status First published Last updated Effective Date
Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated on 12 October 2017 (English only)   2017-10-12    

Final GVP modules

Back to top

Document(s) Language Status First published Last updated Effective Date
Guideline on good pharmacovigilance practices: Module I – Pharmacovigilance systems and their quality systems (English only) adopted 2012-06-25   2012-07-02
Guideline on good pharmacovigilance practices: Module II – Pharmacovigilance system master file (Rev. 2) (English only) adopted 2012-06-25 2017-03-30 2017-03-31
Guideline on good pharmacovigilance practices: Module III – Pharmacovigilance inspections (English only) adopted 2012-12-13 2014-09-15 2014-09-16
Guideline on good pharmacovigilance practices (GVP) - Module IV – Pharmacovigilance audits (Rev. 1) (English only) adopted 2015-08-11    
Guideline on good pharmacovigilance practices: Module V – Risk management systems (Rev. 2) (English only) adopted 2012-06-25 2017-03-30 2017-03-31
Guideline on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products (Rev. 1) (English only) adopted 2012-06-25 2014-09-15 2014-09-16
Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev. 2) (English only) adopted 2012-06-25 2017-08-02 2017-11-22
Guideline on good pharmacovigilance practices (GVP) - Module VI Addendum I – Duplicate management of suspected adverse reaction reports (English only) adopted 2012-06-25 2017-08-02 2017-11-22
Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report (English only) adopted 2012-06-25 2013-12-12 2013-12-13
Guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies (Rev. 3) (English only) adopted 2012-06-25 2017-10-12 2017-10-13
Guideline on good pharmacovigilance practices (GVP) - Module VIII Addendum I – Requirements and recommendations for the submission of information on non-interventional post-authorisation safety studies (Rev. 2) (English only) adopted 2012-06-25 2016-08-08 2016-08-09
Guideline on good pharmacovigilance practices: Module IX – Signal management (English only) adopted 2012-06-25   2012-07-02
Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1) (English only) adopted 2017-10-12   2017-11-22
Guideline on good pharmacovigilance practices (GVP): Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions (English only) adopted 2017-10-12   2017-11-22
Guideline on good pharmacovigilance practices: Module X – Additional monitoring (English only) adopted 2013-04-25   2013-04-25
Guideline on good pharmacovigilance practices: Module XV – Safety communication (Rev. 1) (English only) adopted 2013-01-24 2017-10-12 2017-10-13
Guideline on good pharmacovigilance practices: Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev. 2) (English only) adopted 2014-02-28 2017-03-30 2017-03-31
Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum I – Educational materials (English only) adopted 2015-12-15   2015-12-16

Related links

Final GVP product- or population-specific considerations

Back to top

Final GVP annex I - Definitions

Back to top

Document(s) Language Status First published Last updated Effective Date
Guideline on good pharmacovigilance practices: Annex I - Definitions (Rev. 4) (English only) adopted 2012-06-25 2017-10-12 2017-10-13

Final GVP annex II - Templates

Back to top

Related links

For other templates developed outside the GVP process, see:

Final GVP annex III - Other pharmacovigilance guidance

Back to top

Final GVP annex IV - International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines for pharmacovigilance

Back to top

Document(s) Language Status First published Last updated Effective Date
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 A: Clinical safety data management: Definitions and standards for expedited reporting - Step 5 (English only) adopted 1995-06-01   1995-06-01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2B (R3): Electronic transmission of individual case safety reports (ICSRs) - data elements and message specification - implementation guide - Step 5 (English only) adopted 2005-09-01 2013-08-27 2013-07-01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 B (R3): Questions and answers: Data elements for transmission of individual case safety reports - Step 5 (English only) adopted 2005-03-01 2017-07-27 2016-07-28
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2C (R2) on periodic benefit-risk evaluation report - Step 5 (English only) adopted 2012-12-31   2013-01-01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 D: Postapproval safety data management - Step 5 (English only) adopted 2003-11-30   2004-05-01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 E: Pharmacovigilance planning - Step 5 (English only) adopted 2004-12-31   2005-06-01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2F on development safety update report - Step 5 (English only) adopted 2010-09-30   2011-09-01

Related links

Final GVP annex V - Abbreviations

Back to top

Document(s) Language Status First published Last updated Effective Date
Guideline on good pharmacovigilance practices: Annex V – Abbreviations (Rev. 1) (English only) adopted 2013-04-25 2017-10-12 2017-10-13

Draft GVP chapters and annexes for public consultation

Back to top

Document(s) Language Status First published Last updated Effective Date
Draft guideline on good pharmacovigilance practices (GVP) - Product- or population-specific considerations IV: paediatric population (English only) draft: consultation open 2017-08-02    

Submissions of comments

Back to top

Document(s) Language Status First published Last updated Effective Date
Submission of comments on GVP product- or population-specific considerations IV: Paediatric population (English only)   2017-08-02    

Privacy statement for public consultation

Back to top

Document(s) Language Status First published Last updated Effective Date
Specific privacy statement: Public consultation of good pharmacovigilance practices (English only)   2012-02-22    

Related links